Clinical Trial

Safety and Early Efficacy of iPSC-Derived Motor Neuron Progenitor Cells (XS228) in Subacute Spinal Cord Injury: A Phase I Trial

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This Phase I clinical trial is designed to evaluate the safety, tolerability of XS228 ( iPSC-Derived Motor Neuron Progenitor Cells) in patients with Subacute Spinal Cord Injury
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-05-08; most recent amendment 2025-11-19.
Status change: Not Yet Recruiting → Recruiting 2025-08-09
Trial Details
NCT Number NCT06976229
Lead Sponsor XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.
Collaborators: Third Affiliated Hospital, Sun Yat-Sen University
Conditions Spinal Cord Injury, Safety, Clinical Trials, Efficacy, Induced Pluripotent Stem Cells, Human Motor Neuron Progenitor, Transplantation
Enrollment 12 participants
Start Date 2025-07-02
Primary Completion 2028-02-21 (estimated)
Study Completion 2028-05-30 (estimated)
Updated on ClinicalTrials.gov 2025-11-25